EPISODE · Oct 22, 2025 · 48 MIN
Andrew Bellinger on contrarian bets — and pioneering gene editing at Verve
from Transcribed
Andrew Bellinger discusses what it takes to build new drug modalities from scratch, the bold bets and tough calls that shaped Verve’s journey, and lessons in building new companies from first-in-class science.* Editor's note: The interview was recorded following the announcement of Verve's acquisition by Lilly, which has since been completed.
What this episode covers
Andrew Bellinger discusses what it takes to build new drug modalities from scratch, the bold bets and tough calls that shaped Verve’s journey, and lessons in building new companies from first-in-class science. * Editor's note: The interview was recorded following the announcement of Verve's acquisition by Lilly, which has since been completed.
NOW PLAYING
Andrew Bellinger on contrarian bets — and pioneering gene editing at Verve
No transcript for this episode yet
Similar Episodes
Jul 1, 2026 ·51m
Jun 13, 2026 ·58m
May 10, 2026 ·48m
May 10, 2026 ·324m
Mar 26, 2026 ·546m
Feb 28, 2026 ·589m